VRCA · Verrica Pharmaceuticals
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common warts. It also develops VP-315, an oncolytic peptide-based injectable therapy that is in phase II clinical trial for the treatment of dermatology oncologic conditions, which include basal cell carcinoma and other dermatological oncology indications. The company has a collaboration and license agreement with Torii Pharmaceutical Co., Ltd. for the development and commercialization of its product candidates for the treatment of molluscum and common warts in Japan; and a license agreement with Lytix Biopharma AS to develop and commercialize VP-315 for use in malignant and pre-malignant dermatological indications. Verrica Pharmaceuticals Inc. was incorporated in 2013 and is headquartered in West Chester, Pennsylvania.
Market Cap
53.94M
52 Wk Range
$2.77 - $9.82
Previous Close
$3.14
Open
$3.21
Volume
42,843
Day Range
$2.83 - $3.21
Enterprise Value
53.88M
Cash
14.39M
Avg Qtr Burn
-9.039M
Insider Ownership
49.00%
Institutional Own.
28.11%
Qtr Updated
Sep 30th 2026
